We have verified that AS/BJO-NEs can play an anti-tumor role by down-regulating CDK1 and subsequently reducing the expression of MTFR2, as well as inhibiting the proliferation, migration and invasion capabilities of OSCC cells and the EMT process. Here, MTFR2 is linked to neoplasm.